If chronic kidney disease and heart failure predominate, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RA) were recommended, as were basal insulin and sulfonylureas if A1c (glycated hemoglobin) exceeded the individual target level [16]. This evidence concerns the gene GLP1R and heart failure.